Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ClonoSEQ
Eligibility
Inclusion Criteria:
- Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
CAR infusion
- CAR-T product must meet manufacturer specifications
- PET measurable disease at the time a decision is made to prescribe CAR treatment
- Has sample from diagnosis or relapse available for genomic DNA extraction to identify
patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion Criteria:
- Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
clonotype identified by clonoSEQ, those patients will be removed from the study and
excluded from analysis, but their samples will continued to be stored for future
analysis as improvements to the analysis platform are made.
- No patients are to be excluded on the basis of gender, race, ethnic background, sexual
orientation, or other demographic characteristics.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell
+1 650-725-1647
I'm interested
Psoriasis Clinical Trials
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ClonoSEQ
Eligibility
Inclusion Criteria:
- Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
CAR infusion
- CAR-T product must meet manufacturer specifications
- PET measurable disease at the time a decision is made to prescribe CAR treatment
- Has sample from diagnosis or relapse available for genomic DNA extraction to identify
patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion Criteria:
- Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
clonotype identified by clonoSEQ, those patients will be removed from the study and
excluded from analysis, but their samples will continued to be stored for future
analysis as improvements to the analysis platform are made.
- No patients are to be excluded on the basis of gender, race, ethnic background, sexual
orientation, or other demographic characteristics.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell
+1 650-725-1647
I'm interested
Dermatology Clinical Trials
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ClonoSEQ
Eligibility
Inclusion Criteria:
- Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
CAR infusion
- CAR-T product must meet manufacturer specifications
- PET measurable disease at the time a decision is made to prescribe CAR treatment
- Has sample from diagnosis or relapse available for genomic DNA extraction to identify
patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion Criteria:
- Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
clonotype identified by clonoSEQ, those patients will be removed from the study and
excluded from analysis, but their samples will continued to be stored for future
analysis as improvements to the analysis platform are made.
- No patients are to be excluded on the basis of gender, race, ethnic background, sexual
orientation, or other demographic characteristics.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell
+1 650-725-1647
I'm interested
Pediatric Dermatology Clinical Trials
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ClonoSEQ
Eligibility
Inclusion Criteria:
- Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
CAR infusion
- CAR-T product must meet manufacturer specifications
- PET measurable disease at the time a decision is made to prescribe CAR treatment
- Has sample from diagnosis or relapse available for genomic DNA extraction to identify
patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion Criteria:
- Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
clonotype identified by clonoSEQ, those patients will be removed from the study and
excluded from analysis, but their samples will continued to be stored for future
analysis as improvements to the analysis platform are made.
- No patients are to be excluded on the basis of gender, race, ethnic background, sexual
orientation, or other demographic characteristics.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell
+1 650-725-1647
I'm interested
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ClonoSEQ
Eligibility
Inclusion Criteria:
- Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
CAR infusion
- CAR-T product must meet manufacturer specifications
- PET measurable disease at the time a decision is made to prescribe CAR treatment
- Has sample from diagnosis or relapse available for genomic DNA extraction to identify
patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion Criteria:
- Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
clonotype identified by clonoSEQ, those patients will be removed from the study and
excluded from analysis, but their samples will continued to be stored for future
analysis as improvements to the analysis platform are made.
- No patients are to be excluded on the basis of gender, race, ethnic background, sexual
orientation, or other demographic characteristics.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell
+1 650-725-1647
I'm interested
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ClonoSEQ
Eligibility
Inclusion Criteria:
- Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
CAR infusion
- CAR-T product must meet manufacturer specifications
- PET measurable disease at the time a decision is made to prescribe CAR treatment
- Has sample from diagnosis or relapse available for genomic DNA extraction to identify
patient's clonotype via clonoSEQ (see lab manual for details)
Exclusion Criteria:
- Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
clonotype identified by clonoSEQ, those patients will be removed from the study and
excluded from analysis, but their samples will continued to be stored for future
analysis as improvements to the analysis platform are made.
- No patients are to be excluded on the basis of gender, race, ethnic background, sexual
orientation, or other demographic characteristics.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janet McDowell
+1 650-725-1647
I'm interested